The Clinical Comparison Between PKEP And PKRP Used For BPH With Bladder Degeneration

Objective: To analyze whether there are differences in postoperative outcomes between patients with BPH and bladder aging treated with PKRP and PKEP.Methods: From December 2015 to December 2016,patients who were diagnosed with benign prostatic hyperplasia and diagnosed with bladder aging at the urology center of People’s Hospital of Xinjiang Uygur Autonomous Region were collected.The pathological diagnosis after PKEP or PKRP was confirmed as BPH.The patient’s case data were retrospectively analyzed.PKRP group completed 67 cases,PKEP group completed 59 cases,a total of 126 cases.Results: There was no difference in preoperative general data between PKRP and PKEP.Comparing the hemoglobin values between the two groups,the postoperative HGB value was significantly greater in the PKEP group than in the PKRP group.There was no significant difference in the duration of surgery and the number of days of indwelling catheters between the two groups.The PKEP group was less than PKRP in terms of the number of consecutive days of bladder saline washing and the number of days after hospitalization.Intraoperative removal of hyperplastic prostatic gland volume,PKEP is greater than PKRP.After the two groups of subjects were followed up after surgery,the IPSS score,QOL score,Qmax value,PV,PVR,and tPSA were improved compared with those before the operation,with statistical significance.At the 6th and 12 th months after operation,IPSS was better than PKRP in the two groups.QOL scores were followed up at 3,6 and 12 months after operation.The results showed that PKEP was superior to PKRP,and the difference was statistically significant.After Qmax was followed up at 6th and 12 th months,PKEP was significantly better than PKRP.Postoperative follow-up of PVR,PV,tPSA was statistically significant.PKEP was superior to PKRP.Conclusion: The PKEP group is better able to treat patients with benign prostatic hyperplasia and bladder aging,and has a more definite effect on patients with lower urinary tract symptoms caused by benign prostatic hyperplasia and bladder aging.PKEP worth promoting in clinical use.